• Manufacturing

Pharmaron Acquires State-of-the-Art Biomanufacturing Site in the United Kingdom from AbbVie

Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”) announced today that it has entered into a definitive agreement to acquire Allergan Biologics Limited (“The ABL site”) in Liverpool, UK, for US$118.7 million in cash from AbbVie. The transaction is expected to close in the second quarter of 2021, subject to the satisfaction of customary closing conditions.

Cognate BioServices, and its gene therapy division Cobra Biologics Announce Major Expansion of Manufacturing Facilities in US and Europe

Cobra is undertaking a multi-phase augmentation of its plasmid DNA services as a continuation of its Advanced Therapy expansion project

Late Model Lab and Solid Dose Equipment Available in Massachusetts, USA

Leading asset management company, EquipNet, is working with a leading clinical-stage biopharmaceutical company to sell through surplus laboratory/analytical and solid dose equipment.

Pharmaceutical Investment Recovery & Redeployment Solutions

Sell or redeploy equipment from multiple sites within your company with EquipNet’s Surplus Asset Management Program.

Arcinova announces major investment in Alnwick site with the installation of the R1000 capsule fill machine from 3P Innovation

Arcinova, a multi-service Contract Development and Manufacturing Organisation (CDMO) based in Alnwick, Northumberland, has recently taken delivery and commissioned the award winning R1000 Robotic Capsule Filler from life-sciences automation company 3P innovation, as part of the ‘Fill-Inova’ project.

Cobra Biologics selected to manufacture plasmids for clinical trial of Scancell’s COVID-19 vaccine

The collaboration will ensure GMP production of material for the Phase 1 clinical trial of Scancell’s DNA vaccine against SARS-CoV-2

Cytiva launches Xcellerex Automated Perfusion System for more efficient manufacture of biotherapeutics

Cytiva introduces the Xcellerex Automated Perfusion System (APS), an innovation to the market that supports the biotech industry’s move to continuous manufacturing.

CombiGene and CGT Catapult collaboration completes development of quality control analytical assays for clinical production of CombiGene’s AAV-based gene therapy for the treatment of epilepsy

The extensive and advanced work to develop the critical analytical assays needed for quality control in the manufacture of the AAV1 based gene therapy product CG01 has now been completed in a collaboration between CombiGene and CGT Catapult. CombiGene will now integrate the analytical assays into its production process, taking it another step closer to its final large scale production design for clinical trials and commercial distribution.

Cytiva invests for global capacity expansion

Cytiva, a global life sciences leader, is expanding its manufacturing capacity and hiring personnel in key areas to support the long-term growth of the biotechnology industry.

CombiGene and Cobra Biologics sign agreement to secure GMP production of plasmids for production of CombiGene's gene therapy CG01

The agreement is part of preparations for GMP production of material for the first clinical study of CG01